Halozyme Therapeutics (HALO) Cash & Equivalents (2010 - 2026)
Halozyme Therapeutics' Cash & Equivalents was $163.14 million in Q2 2026, up 163.7% from $61.86 million a year earlier but down 47.3% from the prior quarter.
Powered by 
Analysis
Halozyme Therapeutics (HALO) Cash & Equivalents (2010 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Halozyme Therapeutics came in at $133.82 million, up 15.5% from FY2024.
- Cash & Equivalents shows a five-year compound annual growth rate of -2.0% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $115.85 million in FY2024 (-2.1%), $118.37 million in FY2023 (-49.5%), $234.2 million in FY2022 (+97.3%) and $118.72 million in FY2021 (-19.6%).
- Quarterly Cash & Equivalents has moved between $61.86 million (Q2 2025) and $491.68 million (Q3 2021) over five years.
- Compared with a year earlier, Cash & Equivalents has increased for four straight quarters, with growth averaging 40.1% over the last eight quarters.
- The best year-over-year quarter for Cash & Equivalents over five years was Q3 2021 (growth of 647.9%); the worst was Q2 2022 (a decline of 79.7%).
- Per Business Quant data, HALO's Cash & Equivalents in the three quarters before Q2 2026 was $309.75 million (Q1 2026), $133.82 million (Q4 2025) and $419.67 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Halozyme Therapeutics | 12.53 Bn | 11.13 Bn | 401.83 Mn | 163.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 163.14 Mn |
| Mar 31, 2026 | 309.75 Mn |
| Dec 31, 2025 | 133.82 Mn |
| Sep 30, 2025 | 419.67 Mn |
| Jun 30, 2025 | 61.86 Mn |
| Mar 31, 2025 | 176.33 Mn |
| Dec 31, 2024 | 115.85 Mn |
| Sep 30, 2024 | 154.32 Mn |
| Jun 30, 2024 | 187.86 Mn |
| Mar 31, 2024 | 164.63 Mn |
| Dec 31, 2023 | 118.37 Mn |
| Sep 30, 2023 | 274.23 Mn |
| Jun 30, 2023 | 221.17 Mn |
| Mar 31, 2023 | 96.38 Mn |
| Dec 31, 2022 | 234.20 Mn |
| Sep 30, 2022 | 147.16 Mn |
| Jun 30, 2022 | 90.93 Mn |
| Mar 31, 2022 | 117.84 Mn |
| Dec 31, 2021 | 118.72 Mn |
| Sep 30, 2021 | 491.68 Mn |
API Access
Halozyme Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=HALO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "HALO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=HALO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();